Navigation Links
GlaxoSmithKline Statement on New Information Relating to Manufacture of Rotarix (Rotavirus Vaccine)
Date:3/22/2010

LONDON, March 22 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today confirmed  that it has notified regulatory authorities of the presence of material from a virus called PCV-1 in its oral rotavirus vaccine, Rotarix™.  PCV-1 does not multiply in humans and is not known to cause illness in humans (1)(2). It is found in everyday meat products and is frequently eaten with no resulting disease or illness.

The material was first detected following work done by a research team in the US using a novel technique for looking for viruses and then confirmed by additional tests conducted by GlaxoSmithKline.  

Having reviewed the information and data submitted by GlaxoSmithKline, as well as information available regarding PCV-1 from the world's literature, the European Medicines Agency (EMA) and the World Health Organization (WHO) will also be issuing statements today confirming the positive balance of benefits and risks of the vaccine despite the presence of the material from PCV-1 and have not  recommended any change to the way that healthcare practitioners in Europe and the developing world use Rotarix.  

The US Food and Drug Administration (FDA) similarly has issued a statement confirming that there is no evidence that this finding poses a safety risk based on the excellent safety profile of Rotarix and evidence that PCV-1 is a known virus that does not multiply in humans and is not known to cause illness in humans. Rotarix has been produced according to FDA standards as reviewed and approved for US licensure in 2008. This notwithstanding, the FDA is recommending that US clinicians and public health professionals temporarily suspend the use of Rotarix as a precautionary measure. The FDA have also stated that they intend to convene an advisory committee, within approximately four to six weeks, to review the available data and make recommendations on rotavirus vaccines licensed in the USA.  The FDA will also seek input on the use of new techniques for identifying viruses in vaccines.

Thomas Breuer, Head of Global Clinical R&D and Chief Medical Officer of GSK Biologicals stated: "No safety issue has been identified by external agencies or GSK.  GSK is committed to patient safety and to the highest manufacturing standards for all our vaccines and medicines. We are already working closely and discussing this finding with regulatory agencies around the world."

The safety profile of Rotarix is based on extensive clinical data from the largest vaccine clinical trial programme conducted by GSK, enrolling more than 90,000 participants in Europe, Latin America, Asia, Africa and the US.

Additionally, the post marketing surveillance data represents more than 69 million doses of Rotarix vaccine distributed globally and reflects an excellent safety profile.

Retrospective testing of Rotarix, using new molecular detection techniques, has confirmed that material from PCV-1 has been present since the initial stages of the vaccine's development in the cell bank and rotavirus seeds used as base production material.

GSK is now reviewing how best to replace, in a timely way, the cell bank and virus seeds used as base production material. In the meantime, and in accordance with the regulators, the company will continue to manufacture Rotarix to the existing approved production and quality standards to meet public health needs worldwide.

Rotavirus is the leading cause of severe gastroenteritis among children below five years of age and it is estimated that more than half a million children die of rotavirus gastroenteritis each year- a child a minute worldwide. It is predicted that rotavirus vaccination could prevent more than 2 million rotavirus deaths over the next decade. The continued availability of rotavirus vaccines around the world remains critical from a public health perspective to protect children from rotavirus disease.  

Notes to Editors

Rotarix™

Rotarix is a two-dose, orally-administered vaccine that offers protection against rotavirus to infants. Rotarix is indicated for the active immunisation of infants from the age of 6 weeks for prevention of gastro-enteritis due to rotavirus infection.

Worldwide Rotarix sales in 2009 were 282million pounds Sterling with US representing 76million pounds Sterling.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.

References

1. Linlin Li, Journal of Virology, Feb. 2010, p. 1674–1682

2. Hattermann, Kim. Xenotransplantation 2004: 11: 284–294

SOURCE GlaxoSmithKline

Back to top

RELATED LINKS
http://www.gsk.com

'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline Grants $360,000 to Nine Healthcare Nonprofits - Each to Receive $40,000
2. AAHSA Statement on Passage of Health Reform Legislation
3. Statement by Irwin Redlener, MD, President, Childrens Health Fund on Passage of a Health Care Reform Package by the House
4. Statement from Vicki Escarra, President and CEO, Feeding America, on the Child Nutrition Reauthorization Draft Legislative Proposal
5. Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, on the Beginning of the Reconciliation Process for Health Reform Legislation
6. Statement From Reverend Al Sharpton, Former Congressman J.C. Watts, and Dr. Gary A. Puckrein on the Meeting Between the Congressional Black Caucus and the White House
7. ATS issues statement on disorder of respiratory and autonomic nervous system regulation
8. AHIP Statement on the Status of Health Care Reform
9. Statement from Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, On the Therapy Cap Coalition Press Conference
10. Pelosi Statement in Recognition of Women’s History Month
11. AHIP Statement on H.R. 4626
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
Breaking Medicine Technology: